CureTalks launches its new series featuring biotech companies at the cutting edge of innovation and breakthrough research with the purpose of bringing their contributions to the fore and informing the patient community. This talk series will…
Hydroxychloroquine, When Politics And Science Intersect
TrialX assists academic medical centers in recruitment for clinical research by offering iConnect, a patient friendly, centralized trial listing and recruitment platform. We proudly support research recruitment at Penn Medicine, Indiana CTSI, NYU and BIDMC. Below…
Time magazine named CAR-T cell therapy pioneer Dr Carl June of University of Pennsylvania in their 2018 TIME 100 annual list of the 100 most influential people in the world. We had the opportunity to talk…
CAR T-Cell Immunotherapy has been named Advance of the Year in Annual ASCO Report. Cancer experts looking back over the past 12 months have highlighted adoptive immunotherapy with chimeric antigen receptor (CAR) T cells as the…
Two radically new gene based immunotherapies were approved by the FDA this year – Kymriah followed by Yescarta – in August and October, respectively. Approved in August 2017, before Novartis named the drug Kymriah (Tisagenlecleucel) – it…
As the Superbowl mania grips the football fans across the country this weekend, we at TrialX have been gripped with the launch of new suite of tools to enable patients to learn about new cures and…
